Aduro BioTech, Inc.
(NASDAQ : ADRO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
VTLVital Therapies, Inc.
1.50%13.513.3%$792.68m
AMGNAmgen Inc.
2.36%204.021.3%$749.47m
GILDGilead Sciences, Inc.
0.43%63.140.9%$384.23m
CELGCelgene Corporation
1.53%94.741.3%$360.74m
ILMNIllumina, Inc.
0.49%286.173.5%$321.19m
BIIBBiogen Inc.
1.78%231.681.3%$305.34m
VRTXVertex Pharmaceuticals Incorporated
2.11%184.941.9%$260.38m
EXASExact Sciences Corporation
1.35%119.8224.1%$245.81m
ALXNAlexion Pharmaceuticals, Inc.
1.66%110.852.0%$238.74m
REGNRegeneron Pharmaceuticals, Inc.
1.28%296.852.6%$212.35m
AAgilent Technologies, Inc.
2.18%71.111.6%$206.33m
SRPTSarepta Therapeutics, Inc.
2.44%124.9514.7%$156.17m
INCYIncyte Corporation
3.11%83.122.5%$97.22m
BMRNBioMarin Pharmaceutical Inc.
6.65%76.504.3%$91.98m
SGENSeattle Genetics, Inc.
3.25%79.206.5%$90.21m

Company Profile

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.